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Abstract
Background: Patients with idiopathic pulmonary fibrosis (IPF) undergoing pulmonary resection for lung cancer carry risks of
acute exacerbations of IPF (AE) postoperatively. Currently, agents which may attenuate AE are actively sought. Urinary
trypsin inhibitor, ulinastatin, is a synthetic glycoprotein which may potentially inhibit various inflammatory factors
associated with the development and progression of IPF. The present study was done to evaluate the effects of
administration of high dose ulinastatin in lung cancer patients with IPF immediately following lung resection.
Methods: Patients with IPFs radiologically diagnosed on high resolution CT, and histologically diagnosed resectable lung
cancers, were eligible for the study. The effects of escalating doses of ulinastatin 3610
5,6 610
5, and 9610
5 units/body/day,
administered postoperatively for 3 days were evaluated. The endpoints were safety and feasibility.
Results: Nine patients were evaluated, in cohorts of 3 patients per dosage. Postoperative follow up ranged from 3 to 12
months (median 9 months). The postoperative courses were uneventful in all patients. No subjective adverse events such as
abdominal symptoms or skin rashes, or objective adverse events as per serum laboratory tests, such as liver or kidney
dysfunctions potentially attributable to ulinastatin administration were observed. AE was seen in one patient at 3 months
after surgery, but since this occurred shortly after administration of chemotherapy, it was considered to be attributable to
the chemotherapy rather than surgery.
Discussion: Ulinastatin administration after lung resection in lung cancer patients with IPF was considered to be safe and
feasible. Further study is planned at the highest dose of this study to evaluate efficacy.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is defined as a specific
form of chronic, progressive fibrosing interstitial pneumonia of
unknown cause, occurring primarily in older adults, limited to
the lungs, and associated with histopathologic and/or radio-
logic pattern of usual interstitial pneumonia (UIP). Patients
with IPF have been reported to have an increased risk of
developing lung cancer compared with patients without IPF
[1,2], but there are also contradicting reports [3] and the
evidence is currently conflicting.
IPFs are usually characterized by slowly progressive respiratory
insufficiency. Nevertheless, some IPF patients experience acute
exacerbations of IPF (AE) generally characterized by sudden onset
of progressive, and severe respiratory failure, with rapid
appearances of new lung opacities. This condition is frequently
lethal since there is no established treatment for AE. According to
a recent survey in Japan, the frequency of AE after surgical
resection for lung cancer was reported to be 8.3%, and 41.9% of
these patients died of AE [4].
Ulinastatin, or urinary trypsin inhibitor (MiracridH,M o c h i d a
Pharmaceutical Co. Ltd., Tokyo, Japan) is a synthetic glycopro-
tein with a molecular weight of 67 kDa, first purified from human
urine. It is frequently used clinically for the treatment of shock [5]
and acute pancreatitis [6]. Ulinastatin is also known to inhibit
various inflammatory factors associated with the development
and progression of IPF, such as cytokines [7], oxygen radicals [8]
and adhesion molecules [9]. In experimental studies, high dose,
ulinastatin has been shown to have protective effects against
radiation induced lung fibrosis in mice (2610
5 units/kg) [10], and
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5 units/kg) [11]. According to the pharmaceutical
reference of ulinastatin, side effects have been reported in 74 out
of 8710 patients (0.8%) at doses up to of 3610
5 units/day. These
included abnormalities in serum tests such as elevations in liver
enzymes, abdominal symptoms, skin rashes, and angialgias after
intravenous administrations In clinical studies, administration of
ulinastatin after lung resection for lung cancer has been shown to
be safe at a dose of 3610
5 units/day for 4 days [12,13]. It has
also been reported that administration of high dose ulinastatin
9610
5 units/day resulted in clinical as well as radiological
improvements of interstitial pneumonia in patients with connec-
tive tissue diseases [14,15].
In view of these basic as well as clinical reports on the potential
efficacy of ulinastatin on IPF, the present study was done to
evaluate the effects of administration of high dose ulinastatin in
lung cancer patients with IPF immediately following lung
resection. The endpoints were safety and feasibility.
Materials and Methods
Patients
Patients between 20 and 80 years of age visiting our institution
were considered for the study. The diagnosis of IPF was based on
radiological findings on CT. Patients with IPF, and histologically
diagnosed resectable lung cancers were eligible for the study. The
diagnosis of IPF was made on a high resolution CT by two
diagnostic radiologists certified by the Japan Radiological Society
(M.I. and H.S.) with 13 and 15 years of clinical experiences,
respectively. Diagnoses were made independently, and the two
radiologists discussed when they turned out to be different. In the
diagnostic criteria, the presence of honeycomb lung, subpleural
predominance was necessary. At least one feature of tractional
bronchitis, bronchiole ectasia, ground grass opacity, or consolida-
tion was also necessary. The criteria are according to the general
rules for Diagnosis and Treatment of Idiopathic Interstitial
Pneumonias as described by The Japanese Respiratory Society
[16]. The histology and tumor-node-metastasis classification were
classified according to the general rules for clinical and pathologic
recording of lung cancer as described by the Japan Lung Cancer
Society [17].
Further inclusion criteria were a performance status of 0 or 1,
adequate hematologic, hepatic, renal, and cardiac function
diagnosed within 2 weeks before the registration, (white blood
cells .=3,000/mm
3–,=12,000/mm
3, neutrophils count 1,500/
mm
3–5000/mm
3, platelets count .=75,000/mm
3, hemoglobin
.=8.0 g/dL, aspartate aminotransferase and alanine amino-
Figure 1. CONSORT flowchart of this trial.
doi:10.1371/journal.pone.0029053.g001
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bilirubin ,1.5 mg/dL, creatinine under 1.5 times the upper
institutional limit, normal electrocardiogram, and SpO2.90% at
room air), and being capable of tolerating general anesthesia.
The exclusion criteria were diagnoses of asbestosis, association
with connective tissue diseases, chronic hypersensitivity pneumo-
nitis, and sarcoidosis. Patients with documentations of allergic
reactions against ulinastatin, or who were pregnant or lactating
were also excluded.
Study protocol
The study was carried out in the Division of General Thoracic
Surgery, School of Medicine, Keio University, Japan, according to
the standards of Good Clinical Practice for Trials on Medicinal
Products in Japan. The protocol was approved by Institutional
review board in Keio University School of medicine (no. 2009-73).
Written informed consent was obtained from all of the patients
before undergoing a screening evaluation to determine eligibility.
(The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.)
The primary endpoint was safety. Laboratory assessments
including peripheral blood analyses, liver and kidney functions,
were conducted on days 1, 3, 7, and 1 month after administration
of ulinastatin. Any adverse events and changes in laboratory values
were graded according to the National Cancer Institute Common
Toxicity Criteria version 4.0. An independent data safety
monitoring board (DSMB) consisting of three institutional
members not involved in this study, one pneumologist, one
radiologist, and one general surgeon, evaluated the data analyses,
complications, and side effects. DSMB reviewed the data before
the each case entered the trial. During the administration of
ulinastatin, DSMB checked the data every day. After the
administration, DSMB checked the data weekly until one month
after surgery. The follow up period of this study was one month,
but any latent side effects which were detected during subsequent
patient follow up, which were suspected to be potentially
attributable to ulinastatin administration were to be reported
and evaluated.
All ulinastatin administrations were done in hospitalized
patients. A predetermined dose of ulinastatin was administered 9
times per patient. Ulinastatin was intravenously administered as
bolus injections, 2 milliliters per 10
5 units, immediately after
returning to the ward after surgery, and every 8 hours thereafter,
as indicated for the treatment of shock. Three dose level cohorts
were planned, 3610
5 units/body/day, 6610
5 units/body/day,
and 9610
5 units/body/day. Three patients were to be entered for
each dose cohort. Dose escalation was done after one-month-
Table 2. Perioperative factors that may have potentially affected interstitial pulmonary fibrosis status.
P a t i e n t N o . 12 3456789M e a n ±SD, median
Operative time (mins) 345 318 222 353 295 221 197 200 290 271662, 290
Anesthesia time (mins) 449 393 317 455 430 295 261 320 355 364671, 355
One lung ventilation time (mins) 360 320 187 350 310 194 187 186 265 262675, 265
Intraoperative bleeding (ml) 90 177 90 170 277 50 47 133 132 130672, 132
Total intraoperative oxygen (l) 890 1200 650 1800 900 885 550 960 880 9686362, 890
SD: standard deviation.
doi:10.1371/journal.pone.0029053.t002
Table 1. Patient demographics.
Patient No 1 2 3 4 5 6 7 8 9
Mean±SD,
median
Age 73 59 79 69 69 67 54 66 75 6868, 69
sex M M M M M M M M M -
Smoking
(pack/years)
1 0 0 6 0 6 0 3 0 8 0 8 0 3 09 05 0 6 4 625, 60
P S0 0 0 0 0 0 000 -
Comorbidities diabetes none gastric Cancer,
colon cancer,
and renal cancer,
all resected
abdominal
aortic
aneurysm,
stent placed
oral cancer
resected,
gastric
ulcer
laryngeal
cancer,
resected
hypertention hypertention hypertention,
old pulmonary
tuberculosis
-
Predominant
region of IPF
bilateral
lower lobes
bilateral
lower
lobes
bilateral
lower lobes
bilateral lower
lobes
bilateral
lower
lobes
bilateral
lower lobes
bilateral
lower lobes
all lobes bilateral
lower lobes
-
Operative
procedure
left S6
segmentectomy
LLL LUL LLL RUL RUL LLL LUL LLL -
Histology SCLC SQ SQ SQ LCNEC AD AD SQ AD -
p-TNM T1aN0M0 T3N0M0 T2bN0M0 T2aN2M0 T2N2M0 T2aN0M0 T3N0M0 T1bN0M0 T1bN0M0 -
M: male, PS: performance status, SCLC: small cell lung cancer, SQ: squamous cell carcinoma, LCNEC: large cell neuroendocrine carcinoma, AD: adenocarcinoma, LLL: left
lower lobectomy, LUL: left upper lobectomy, RUL: right upper lobectomy, SD: standard deviation.
doi:10.1371/journal.pone.0029053.t001
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If any grade 4 toxicity was seen, the trial was to be stopped. If
grade 3 toxicity was seen, the DSMB was to decide whether the
trial could be continued or not, depending on the condition and
causal relationship to ulinastatin administration.
The secondary endpoint was the incidence of AE. The diagnosis
of AE was based on the fulfillment of all of the following criteria;
1) unexplained worsening or development of dyspnea within 30
days, 2) high-resolution computed tomography with new bilateral
ground-glass abnormality and/or consolidation superimposed on a
background reticular or honeycomb pattern consistent with usual
interstitial pneumonia pattern 3) no evidence of pulmonary
infection by endotracheal aspirate or bronchoalveolar lavage
4) exclusion of alternative causes, including left heart failure,
pulmonary embolism, and other identifiable cause of acute lung
injury [18].
Results
Study population
This trial was conducted from September 2009 to April 2011.
During this period, lung resections were performed in 125 patients
with lung cancer. Of these patients, 22 patients were enrolled in
the present study. Thirteen of these patients did not meet the
radiological criteria for IPF and were excluded. Nine patients were
included in the present study (Figure 1).
The demographic characteristics of the 9 patients are shown in
Table 1. The patients were all males with smoking histories.
Their ages ranged from 54 to 79 years (median 69 years).
Performance status was 0 in all patients. Comorbidities included
histories of other cancers, hypertension, diabetes, and aortic
aneurysm, but were all sufficiently controlled. None of the
patients were taking steroids, immunomodulators or pirfenidone.
Lobectomy was done in 8 patients and segmentectomy was done
in one patient. ND2a-II lymph node dissection (ipsilateral hilar
and mediastinal lymph node dissection) was done in all patients.
Radiological IPFs were seen predominantly in the lower lobes.
UIP was seen histologically in patients No. 1, 2, 4, 7, 8, and 9, in
which the region of resection included the radiological region of
IPF, but was not apparent in other patients. The dosages of
ulinastatin were 3610
5 units/body/day, 6610
5 units/body/day,
and 9610
5 units/body/day, in patients No. 1 to 3, 4 to 6, and 7
to 9, respectively. Intravenous administration of ulinastatin was
feasible in all patients.
Perioperative factors, which may have potentially affected IPF
status, are summarized in Table 2. Moderate variability existed in
the perioperative factors among patients, but it was considered
that operative procedures were completed without significant
complications in all the patients.
Safety
Outcomes after surgery are summarized in Table 3. All patients
were discharged without oxygen. Prolonged lung fistula was seen
in patient No. 8, but otherwise the postoperative outcomes were
uneventful. Symptomatic side effects potentially attributable to
ulinastatin, such as abdominal symptoms or skin rashes were not
seen in any of the patients. AE within one month was not seen in
any of the patients (0/9, 0%, 95% confidence interval of the
estimated population proportion 0–30%). AE was seen in patient
No. 1 at 3 months after surgery, but since this occurred shortly
after administration of chemotherapy, it was considered to be
attributable to chemotherapy rather than surgery. This patient
died of the AE 6 months later. Patient No. 2 died of cancer
progression at 3 months after surgery. Since this patient had stage
IIB disease, and furthermore, no postoperative chemotherapy was
done due to IPF, this early progression was not considered as
exceptional, and was not considered to be related to the
administration of ulinastatin. Other patients are currently alive
without disease.
Results of the serum blood test are summarized in Fig. 2A. The
transient increases in c-reactive proteins were considered to be
primarily due to surgery. Other measurements shifted mostly
within the institutional limits, and side effects attributable to
ulinastatin administration were not apparent. Arterial oxygen
saturation at room air, and sialylated carbohydrate antigen values,
which were measured as indirect indices of IPF status, were also
mostly stable during the observation period (Fig. 2B).
Pulmonary function test results are summarized in Fig. 3.
Postoperative pulmonary function tests were available in patients 5
to 9, and in these patients, the decreases in postoperative percent
of predicted normal vital capacity and percent of predicted normal
forced expiratory volume in 1 second were considered to be
compatible with the performed lung resections.
Table 3. Postoperative outcomes.
P a t i e n t N o . 1 2 345678 9
Mean±SD,
median
Nasal oxygen (days) 8 2 1 1 1111 7 13 . 7 65.5, 1
Hospital stay (days) 11 5 10 10 10 9 8 21 11 10.664.3, 10
Postoperative complications none none none none none none none prolonged
lung fistula
none -
Symptomatic side effects
potentially attributable to
ulinastatin
none none none none none none none none none -
AE within 1 month none none none none none none none none none -
Clinical outcome AE at 3 POM after
chemo-therapy.
Died of AE at
9POM
Died of
cancer
at 3POM
Alive
without
disease
at 1POY
Alive
without
disease
at 9POM
Alive
without
disease
at 9POM
Alive
without
disease
at 9POM
Alive
without
disease
at 6POM
Alive without
disease at
3POM
Alive
without
disease at
3POM
-
POM: postoperative months, POY: postoperative years, SD: standard deviation.
doi:10.1371/journal.pone.0029053.t003
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Treatment for patients with lung cancer combined with IPF is
problematic since idiopathic or iatrogenic AE could occur
following various anticancer treatments. In the case of chemo-
therapy, the previously reported incidences of treatment-related
AE ranged from 5.6% to 21% in Japan [19,20]. The frequency of
AE following conventional radiation therapy for IPF patients is
reported to be around 25% in Japan [21,22]. Therefore,
conventional radiation therapy is considered to be contraindicated
in IPF patients. The indication for stereotactic body radiotherapy
still remains controversial [23]. Epidermal growth factor receptor
tyrosine kinase inhibitors are also contraindicated in patients with
IPF.
As for surgical resection, it has been reported that postoperative
mortality and morbidity for major pulmonary resection is
significantly higher in patients with IPF. Also, the long-term
results tend to be poor due to the high incidence of second primary
lung cancer as well as the poor natural history of IPF itself.
Nevertheless, currently there is no evidence to indicate that
surgical resection is contraindicated in lung cancer patients with
IPF, particularly if the IPF is not considered to be rapidly
progressive at the time of lung cancer diagnosis [24,25,26]. In view
of these clinical data, we believe that the option of surgical
resection should be offered to IPF patients with resectable lung
cancer, if the patient understands and is willing to accept the risks
involved.
Any treatment modality with a potential to attenuate AE
should be actively sought. Treatment of AE has generally
consisted of high-dose corticosteroids with empirical success in
some patients, but there are no data from controlled trials to
prove their efficacy [18,27]. There are also no known agents
which may provide prophylaxis for AE. Furthermore, there are
no established predictive indices for AE [18]. Although the exact
mechanisms are still to be elucidated, it has been reported that
progression of IPF is associated with the production of factors
such as MCP-1 (monocyte chemotactic protein-1) [28], and
TGF-beta (transforming growth factor-beta) [10,29]. Ulinastatin
was first characterized as a protease inhibitor, but its effects seem
to be multifaceted. Recently, it was suggested that serum
concentration of both MCP-1 and TGF-beta were suppressed
by administration of 9610
5 units of ulinastatin in patients with
connective tissue disease associated pulmonary fibrosis [14,15].
We considered that administration of ulinastatin at this dosage
might decrease the incidence and/or severity of AE after lung
resection. Since this dosage is three times the maximum approved
dosage of ulinastatin in Japan, the present study was done to test
the safety and feasibility of this dosage in lung cancer patients
with IPF after lung resection.
In the present study, although the study population is small,
ulinastatin administration after lung resection was considered to be
safe in all patients. Its intravenous administration during the
postoperative period was also considered to be feasible. Further
accumulation of data at a dosage of 9610
5 units of ulinastatin is
planned to evaluate efficacy. In future studies, it would be optimal
to include a comparative control arm. But acquisition of patients’
consents in such studies is expected be difficult because of the
extremely poor outcome after exacerbation of IPF, and the
relatively high safety profile of ulinastatin. A larger scale one-arm
study may be more realistic.
Figure 2. The postoperative changes in the laboratory data are shown. (A) In the serum laboratory data, the measurements shifted mostly
within the institutional limits (dotted lines). The transient increases in c-reactive proteins were seen. POD: postoperative days, POM: postoperative
months, AST: Asparatate Aminotransferase, ALT: Alanine Aminotransferase, LDH: Lactate Dehydrogenase, g-GTP: gamma-Glutamyltranspeptidase. (B)
Arterial oxygen saturation at room air (SpO2), and sialylated carbohydrate antigen (KL-6) values, which were measured as indirect indices of IPF status,
were mostly stable during the observation period.
doi:10.1371/journal.pone.0029053.g002
Figure 3. Postoperative pulmonary function tests were available in 5 patients. In these patients, both percent of predicted normal vital
capacity (%VC) and percent of predicted normal forced expiratory volume in 1 second (FEV1.0%) decreased after lung resections.
doi:10.1371/journal.pone.0029053.g003
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